<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34829769</PMID><DateRevised><Year>2021</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1540</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines9111540</ELocationID><Abstract><AbstractText>Despite the growing number of patients with persistent symptoms after acute SARS-CoV-2 infection, the pathophysiology underlying long-COVID is not yet well characterized, and there is no established therapy. We performed a deep immune profiling in nine patients with persistent symptoms (PSP), before and after a 4-day prednisone course, and five post-COVID-19 patients without persistent symptoms (NSP). PSP showed a perturbed distribution of circulating mononuclear cell populations. Symptoms in PSP were accompanied by a pro-inflammatory phenotype characterized by increased conventional dendritic cells and augmented expression of antigen presentation, co-stimulation, migration, and activation markers in monocytes. The adaptive immunity compartment in PSP showed a Th1-predominance, decreased na&#xef;ve and regulatory T cells, and augmentation of the PD-1 exhaustion marker. These immune alterations reverted after the corticosteroid treatment and were maintained during the 4-month follow-up, and their normalization correlated with clinical amelioration. The current work highlights an immunopathogenic basis together with a possible role for steroids in the treatment for long-COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Utrero-Rico</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8814-8410</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Ruig&#xf3;mez</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1538-3043</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laguna-Goya</LastName><ForeName>Roc&#xed;o</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4265-8567</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arrieta-Ortubay</LastName><ForeName>Est&#xed;baliz</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chivite-Lacaba</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9357-5556</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Cuadrado</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9854-0870</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalueza</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Universidad Complutense de Madrid, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almendro-Vazquez</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4362-1996</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2211-9881</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguado</LastName><ForeName>Jos&#xe9; Mar&#xed;a</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-9520-8255</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Universidad Complutense de Madrid, 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumbreras</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Universidad Complutense de Madrid, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paz-Artal</LastName><ForeName>Estela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense de Madrid, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>COVID-19 research call COV20/00181</GrantID><Agency>Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 research call COV20/00181) - co-financed by the European Development Regional Fund "A way to achieve Europe"</Agency><Country/></Grant><Grant><GrantID>CIVICO study 2020/0082</GrantID><Agency>Consejeria de Sanidad de la Comunidad de Madrid</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">corticosteroids</Keyword><Keyword MajorTopicYN="N">immunological alterations</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34829769</ArticleId><ArticleId IdType="pmc">PMC8614904</ArticleId><ArticleId IdType="doi">10.3390/biomedicines9111540</ArticleId><ArticleId IdType="pii">biomedicines9111540</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Z., Yang M., Lai C.L. Long COVID-19 Syndrome: A comprehensive review of its effect on various organ systems and recommendation on rehabilitation plans. Biomedicines. 2021;9:966. doi: 10.3390/biomedicines9080966.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9080966</ArticleId><ArticleId IdType="pmc">PMC8394513</ArticleId><ArticleId IdType="pubmed">34440170</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A., Bernabei R., Landi F., for the Gemelli Against COVID-19 Post-Acute Care Study Group Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C., Laurent E., Lemaignen A., Beaufils E., Bourbao-Tournois C., Laribi S., Flament T., Ferreira-Maldent N., Bruyere F., Stefic K., et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin. Microbiol. Infect. 2021;27:258&#x2013;263. doi: 10.1016/j.cmi.2020.09.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.052</ArticleId><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E., Janvier P., Kherabi Y., Le Bot A., Hamon A., Gouze H., Doucet L., Berkani S., Oliosi E., Mallart E., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020;81:e4&#x2013;e6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Xu H., Jiang H., Wang L., Lu C., Wei X., Liu J., Xu S. Clinical features and outcomes of discharged coronavirus disease 2019 patients: A prospective cohort study. QJM. 2020;113:657&#x2013;665. doi: 10.1093/qjmed/hcaa178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcaa178</ArticleId><ArticleId IdType="pmc">PMC7313792</ArticleId><ArticleId IdType="pubmed">32442308</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I., Davenport T., Wakefield D., Vollmer-Conna U., Cameron B., Vernon S.D., Reeves W.C., Lloyd A., Dubbo Infection Outcomes Study G. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: Prospective cohort study. BMJ. 2006;333:575. doi: 10.1136/bmj.38933.585764.AE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed H., Patel K., Greenwood D.C., Halpin S., Lewthwaite P., Salawu A., Eyre L., Breen A., O&#x2019;Connor R., Jones A., et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. J. Rehabil. Med. 2020;52:jrm00063. doi: 10.2340/16501977-2694.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/16501977-2694</ArticleId><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Perez O., Merino E., Leon-Ramirez J.M., Andres M., Ramos J.M., Arenas-Jimenez J., Asensio S., Sanchez R., Ruiz-Torregrosa P., Galan I., et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J. Infect. 2021;82:378&#x2013;383. doi: 10.1016/j.jinf.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison P.J. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18:e1003773. doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty S.E., Guo Y., Heath K., Dasmarinas M.C., Jubilo K.G., Samranvedhya J., Lipsitch M., Cohen K. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: Retrospective cohort study. BMJ. 2021;373:n1098. doi: 10.1136/bmj.n1098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1098</ArticleId><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Estiri H., Strasser Z.H., Brat G.A., Semenov Y.R., Patel C.J., Murphy S.N. Evolving phenotypes of non-hospitalized patients that indicate long COVID. BMC Med. 2021;19:249. doi: 10.1186/s12916-021-02115-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02115-0</ArticleId><ArticleId IdType="pmc">PMC8474909</ArticleId><ArticleId IdType="pubmed">34565368</ArticleId></ArticleIdList></Reference><Reference><Citation>Kersten J., Baumhardt M., Hartveg P., Hoyo L., Hull E., Imhof A., Kropf-Sanchen C., Nita N., Morike J., Rattka M., et al. Long COVID: Distinction between organ damage and deconditioning. J. Clin. Med. 2021;10:3782. doi: 10.3390/jcm10173782.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10173782</ArticleId><ArticleId IdType="pmc">PMC8432179</ArticleId><ArticleId IdType="pubmed">34501230</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L.M., Lannigan J., Jaimes M.C. OMIP-069: Forty-Color Full Spectrum Flow Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets in Human Peripheral Blood. Cytom. Part A. 2020;97:1044&#x2013;1051. doi: 10.1002/cyto.a.24213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.24213</ArticleId><ArticleId IdType="pmc">PMC8132182</ArticleId><ArticleId IdType="pubmed">32830910</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)  Novel Coronavirus: COVID-19 Therapeutic Trial Synopsis, 18 February 2020, Switzerland.  [(accessed on 30 September 2021)].  Available online:  www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf.</Citation></Reference><Reference><Citation>Sanchez-Cerrillo I., Landete P., Aldave B., Sanchez-Alonso S., Sanchez-Azofra A., Marcos-Jimenez A., Avalos E., Alcaraz-Serna A., de Los Santos I., Mateu-Albero T., et al. COVID-19 severity associates with pulmonary redistribution of CD1c + DCs and inflammatory transitional and nonclassical monocytes. J. Clin. Investig. 2020;130:6290&#x2013;6300. doi: 10.1172/JCI140335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI140335</ArticleId><ArticleId IdType="pmc">PMC7685723</ArticleId><ArticleId IdType="pubmed">32784290</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Dyer A.H., Naughton A., Kiersey R., Holden D., Gardiner M., Dowds J., O&#x2019;Brien K., Bannan C., Nadarajan P., et al. Longitudinal analysis of COVID-19 patients shows age-associated T Cell changes independent of ongoing Ill-health. Front. Immunol. 2021;12:676932. doi: 10.3389/fimmu.2021.676932.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.676932</ArticleId><ArticleId IdType="pmc">PMC8138306</ArticleId><ArticleId IdType="pubmed">34025675</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk A.J., Rustagi A., Zhao N.Q., Roque J., Martinez-Colon G.J., McKechnie J.L., Ivison G.T., Ranganath T., Vergara R., Hollis T., et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 2020;26:1070&#x2013;1076. doi: 10.1038/s41591-020-0944-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0944-y</ArticleId><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonecchi R., Bianchi G., Bordignon P.P., D&#x2019;Ambrosio D., Lang R., Borsatti A., Sozzani S., Allavena P., Gray P.A., Mantovani A., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 1998;187:129&#x2013;134. doi: 10.1084/jem.187.1.129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.187.1.129</ArticleId><ArticleId IdType="pmc">PMC2199181</ArticleId><ArticleId IdType="pubmed">9419219</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita R., Schmitt N., Bentebibel S.E., Ranganathan R., Bourdery L., Zurawski G., Foucat E., Dullaers M., Oh S., Sabzghabaei N., et al. Human blood CXCR5 (+) CD4 (+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34:108&#x2013;121. doi: 10.1016/j.immuni.2010.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.12.012</ArticleId><ArticleId IdType="pmc">PMC3046815</ArticleId><ArticleId IdType="pubmed">21215658</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S.P., Zhang H.H., Foley J.F., Hedrick M.N., Farber J.M. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J. Immunol. 2008;180:214&#x2013;221. doi: 10.4049/jimmunol.180.1.214.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.1.214</ArticleId><ArticleId IdType="pubmed">18097022</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo G.D., Lazarini F., Levallois S., Hautefort C., Michel V., Larrous F., Verillaud B., Aparicio C., Wagner S., Gheusi G., et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci. Transl. Med. 2021;13:596. doi: 10.1126/scitranslmed.abf8396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf8396</ArticleId><ArticleId IdType="pmc">PMC8158965</ArticleId><ArticleId IdType="pubmed">33941622</ArticleId></ArticleIdList></Reference><Reference><Citation>Du W., Yu J., Liu X., Chen H., Lin L., Li Q. Persistence of SARS-CoV-2 virus RNA in feces: A case series of children. J. Infect. Public Health. 2020;13:926&#x2013;931. doi: 10.1016/j.jiph.2020.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.05.025</ArticleId><ArticleId IdType="pmc">PMC7275988</ArticleId><ArticleId IdType="pubmed">32546439</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Cen M., Hu M., Du L., Hu W., Kim J.J., Dai N. Prevalence and persistent shedding of fecal SARS-CoV-2 RNA in patients with COVID-19 infection: A systematic review and meta-analysis. Clin. Transl. Gastroenterol. 2021;12:e00343. doi: 10.14309/ctg.0000000000000343.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ctg.0000000000000343</ArticleId><ArticleId IdType="pmc">PMC8036078</ArticleId><ArticleId IdType="pubmed">33835096</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuwa H.A., Shaw T.N., Knight S.B., Wemyss K., McClure F.A., Pearmain L., Prise I., Jagger C., Morgan D.J., Khan S., et al. Alterations in T and B cell function persist in convalescent COVID-19 patients. Med. 2021;2:720&#x2013;735. doi: 10.1016/j.medj.2021.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC8011689</ArticleId><ArticleId IdType="pubmed">33821250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhadelia N., Belkina A.C., Olson A., Winters T., Urick P., Lin N., Rifkin I., Kataria Y., Yuen R.R., Sagar M., et al. Distinct autoimmune antibody signatures between hospitalized acute COVID-19 patients, SARS-CoV-2 convalescent individuals, and unexposed pre-pandemic controls. medRxiv. 2021 doi: 10.1101/2021.01.21.21249176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.21.21249176</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter A.G., Shields A.M., Karim A., Birch D., Faustini S.E., Steadman L., Ward K., Plant T., Reynolds G., Veenith T., et al. Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. Clin. Exp. Immunol. 2021;205:99&#x2013;105. doi: 10.1111/cei.13623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13623</ArticleId><ArticleId IdType="pmc">PMC8239842</ArticleId><ArticleId IdType="pubmed">34082475</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>